Skip to main content

NovaBay Pharmaceuticals Announces Significant Orders for DERMAdoctor’s Top-Selling Kakadu C Anti-Aging Serum ahead of the Holiday Season

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces significant orders for DERMAdoctor® Kakadu® C 20% Vitamin C Serum with Ferulic Acid & Vitamin E.

“We are excited to share that one of our best-selling products, DERMAdoctor Kakadu C serum, continues its popularity this year with several large orders just in time for the holiday season,” said Justin Hall, NovaBay CEO. “These orders will favorably impact DERMAdoctor’s revenue contribution for the 2022 third and fourth quarters.”

Best-selling, antioxidant-rich Kakadu C serum helps to visibly brighten and even skin tone while also improving the appearance of skin elasticity, fine lines and wrinkles. This clinical-strength serum features 20% stabilized vitamin C and is formulated with superfruit Kakadu plum, which is wild-harvested in the remote Kimberley region of Australia. The Kakadu plum is one of the richest natural sources of vitamin C on earth, containing on average 55 times more vitamin C that an average Florida orange.

The Kakadu C collection was formulated by NovaBay Chief Product Officer, Audrey Kunin, MD, a board-certified dermatologist. Kakadu C products are hypoallergenic, non-irritating, non-drying, pH balanced, and free of synthetic fragrance and dye. All DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been overlooked by the beauty industry. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, and, as well as through digital beauty retailers including SkinStore, and its own website. DERMAdoctor products are also available internationally through select distributors and retailers.

About NovaBay Pharmaceuticals, Inc.:

NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products. Avenova® is the most prescribed antimicrobial lid and lash spray and DERMAdoctor® is a premium skincare brand offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.

NovaBay Pharmaceuticals Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our business strategies, ability to complete certain financing transactions, current and future product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results (and ability to continue as a going concern) and the impact of a reverse stock split. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the SEC, especially under the heading “Risk Factors,” and in the Preliminary Proxy Statement filed by NovaBay with the SEC, especially under the heading “Proposal Two: The Reverse Stock Split Proposal — Risks Relating to the Reverse Stock Split.” The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBays Progress

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:

Please call 877-337-6237 or email


NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel


Investor Contact

LHA Investor Relations

Jody Cain


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.